Sotera Health Company · NASDAQ:SHC
Sotera Health — Q1 2026 Earnings Presentation
26 slides from Sotera Health's earnings presentation, May 5, 2026
Slide 1: First-Quarter 2026 Earnings Results
Safeguarding Global Health® First-Quarter 2026 Earnings Results May 5, 2026 © 2026 Sotera Health Company | All Rights Reserved.
Slide 2: Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures
Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appro
Slide 3: Speakers
Speakers Michael B. Petras, Jr. Chairman and Chief Executive Officer Jonathan M. Lyons Senior Vice President and Chief Financial Officer © 2026 Sotera Health Company | All Rights Reserved. 2
Slide 4: First-Quarter Performance
First-Quarter Performance “We delivered a strong start to the year, with solid revenue and Adjusted EBITDA growth while driving margin expansion. Growth was driven by disciplined execution at Sterigenics and Nordion, and Nelson Labs came in as we outlined on our fourth- quarter 2025 earnings call. B
Slide 5: Q1 2026 Highlights
Q1 2026 Highlights (1) Performance Net Revenues 10.0%; 6.5% CC (2)(3) Total company delivered solid top- & bottom-line CC growth Expanded Adjusted EBITDA margins Sterigenics: 6.1% CC revenue growth, driven by price and volume/mix improvement Nordion: 25.8% CC revenue growth, with over 290 ba
Slide 6: Q1 2026 Consolidated Financial Performance
Q1 2026 Consolidated Financial Performance $ In millions, except Adjusted EPS and Adjusted EBITDA margin Revenue Adjusted EBITDA Adjusted EPS +10.0% / +6.5% CC +10.5% / +6.9% CC +29% $280 $135 $0.18 $255 $0.14 $122 47.9% 48.1% 2025 2026 2025 2026 2025 2026 © 2026 Sotera Health Company | All Rights R
Slide 7: Sterigenics Q1 2026 Financial Performance
Sterigenics Q1 2026 Financial Performance $ In millions Revenue +9.7% / +6.1% CC Segment Income +9.6% / +6.0% CC $186 • Revenue growth was driven by favorable $170 pricing, foreign currency benefits and improved volume/mix. $88 $96 • Segment Income growth was driven by the above factors, partially o
Slide 8: Nordion Q1 2026 Financial Performance
Nordion Q1 2026 Financial Performance $ In millions Revenue +29.0% / +25.8% CC Segment Income +36.1% / +33.1% CC • Revenue growth was driven by volume/mix benefits due to timing of $42 cobalt-60 harvests, along with foreign $33 currency tailwinds and favorable pricing. $24 • Segment income and segme
Slide 9: Nelson Labs Q1 2026 Financial Performance
Nelson Labs Q1 2026 Financial Performance $ In millions Revenue -0.7% / -3.8% CC Segment Income -11.5% / -15.1% CC • Revenue, segment income and segment $52 $52 income margin differences were driven by unfavorable volume/mix, partially offset by foreign currency benefits and favorable pricing. $16 $
Slide 10: Liquidity, Net Leverage and Investments
Liquidity, Net Leverage and Investments $ In millions $937 $906 $687 $592 $592 • Continued strong cash and liquidity position $410 Liquidity • No outstanding borrowings on revolving line of credit $277 $345 $314 12/31/24 12/31/25 3/31/26 Unrestricted Cash Revolver Availability 3.7x 3.2x 3.2x Net • A
Slide 11: 2026 Outlook
2026 Outlook © 2026 Sotera Health Company | All Rights Reserved. 10
Slide 12: Full-year 2026 Outlook Reaffirmed
Full-year 2026 Outlook Reaffirmed FY 2026 Outlook $1,233M to $1,251M Net Revenues +6.0% to 7.5% +5.0 to 6.5% CC $632M to $641M Adjusted EBITDA +6.5% to 8.0% +5.5 to 7.0% CC Interest Expense $135M to $145M Tax Rate Applicable to Adjusted Net Income(1) 27.0% to 29.0% Adjusted EPS $0.93 to $1.01 Weight
Slide 13: Additional 2026 Outlook Items
Additional 2026 Outlook Items • Total company pricing expected to be approximately the mid-point of 3% - 4% long-term range General • Foreign exchange benefit expected to be realized in 1H’26, with the 2H’26 approximately neutral Commentary • Net leverage ratio expected to improve versus 12/31/25 •
Slide 14: Corporate Overview
Corporate Overview © 2026 Sotera Health Company | All Rights Reserved. 13
Slide 15: Safeguarding Global Health
Safeguarding Global Health® Global customer base in over Over 3,000 employees Provide end-to-end Integrated global network of 50 countries solutions for our customers 63 facilities located in in highly-regulated markets 13 countries Customers include 40+ of top 50 medical device companies, Customer
Slide 16: Our Crucial Role in the Healthcare Supply Chain
Our Crucial Role in the Healthcare Supply Chain R&D, materials Pre-FDA filing tests Product Sterilization Quality control Distribution and packaging and clinical trials manufacturing tests optimization ✓✓ ✓✓ ✓ ✓✓✓ ✓✓ ✓ ✓ ✓ © 2026 Sotera Health Company | All Rights Reserved. 15
Slide 17: Three Integrated and Outstanding Business Segments
Three Integrated and Outstanding Business Segments Global leader in comprehensive World’s Largest Provider of Global leader in microbiological sterilization solutions Cobalt-60 sealed sources and analytical lab testing 2,000+ Providing 2,000+ customers Customers(1) (1) peace of Providing customers e
Slide 18: Our Company Key Priorities
Our Company Key Priorities 1 2 3 4 Excellence in Win in growth Driving Disciplined serving our markets operational capital customers with excellence to deployment end-to-end enhance free solutions cash flow Strong Execution to Generate Value for Our Stakeholders © 2026 Sotera Health Company | All Ri
Slide 19: Global Leader Positioned for Sustainable Growth
Global Leader Positioned for Sustainable Growth © 2026 Sotera Health Company | All Rights Reserved. 18
Slide 20: Appendix
Appendix © 2026 Sotera Health Company | All Rights Reserved. 19
Slide 21: Non-GAAP Financial Measures
Non-GAAP Financial Measures (unaudited) (dollars in thousands, except per share amounts) Three Months Ended March 31, 2026 2025 Net income (loss) $ 26,589 $ (13,260) Amortization of intangible assets 5,602 18,674 Share-based compensation(a) 14,442 7,269 Loss on foreign currency and derivatives not d
Slide 22: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) a) Represents share-based compensation expense to employees and Non-Employee Directors. b) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer a
Slide 23: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) (unaudited) (dollars in thousands, except per share amounts) Twelve months Year end December 31, ended March 31 2024 2025 2026 Net income $ 44,398 $ 77,949 $ 117,798 Amortization of intangible assets 79,377 41,798 28,726 Share-based compensation(a) 36,896 31,0
Slide 24: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) a) Represents share-based compensation expense to employees and Non-Employee Directors. b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the refinancing activity for the Term Loans
Slide 25: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) (unaudited) (dollars in thousands) As of December 31, As of March 31, 2024 2025 2026 Current portion of long-term debt 14,803 13,973 13,983 Long-term debt less current portion 2,208,100 2,126,724 2,124,327 Current portion of finance leases 2,923 3,465 3,577 Fi
Slide 26: Non-GAAP Financial Measures Definitions
Non-GAAP Financial Measures Definitions • Adjusted Net Income is defined as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period. • Adjusted EBITDA is defined as Adjusted Net Income be
Sotera Health Company — Q1 2026 Earnings Presentation on 6ix